How Medications Change Your Heart Rate Zones

Short Answer

Heart-rate training zones only work if your heart can answer effort in the usual way: speed up when your muscles need more oxygen, then slow back down as you recover. Many medications change that signal. Beta-blockers are the clearest example. They block adrenaline’s effect on the heart, so your pulse may rise less than expected even when your legs, lungs, and metabolism are doing real work; Mayo Clinic and the American Heart Association both warn that beta-blockers can keep you from reaching your usual target heart rate during exercise. In a double-blind, placebo-controlled crossover trial in 21 healthy young adults, a single dose of bisoprolol lowered resting heart rate by 14 bpm at 2.5 mg and 20 bpm at 5.0 mg, and reduced the chronotropic response to exercise. (Forton et al., *Sports Medicine – Open*, 2022) Those figures come from single doses in healthy volunteers, not from people on long-term therapy — so they are not a correction factor to apply to your own watch. What they do show clearly is that the number has changed meaning. Mayo Clinic puts the practical limit plainly: there is no way to know the exact effect of a beta-blocker on your heart rate, which is why perceived exertion is recommended instead. (mayoclinic.org)

Rate-lowering drugs mean a “zone 2” number on your watch may no longer correspond to zone 2 effort. And the problem starts even before medication, because many zone calculators lean on age-based maximum-heart-rate formulas that are shaky in the first place: "Conventional age-based HRmax prediction formulas, particularly the widely used "220-age" equation, remain common despite substantial individual variation". Recovery and HRV scores can shift too — "Medications, particularly beta-blockers and anticholinergics, dramatically alter HRV independent of disease status". (pubmed.ncbi.nlm.nih.gov)

The practical fix is not to abandon your data. It is to stop treating a formula-derived zone as ground truth. Pair heart rate with how the effort actually feels — breathing, muscle fatigue, talkability, recovery afterward — and build your reference range from your own repeated measurements, not from a generic chart. If you take a heart-rate-changing medication, ask your prescriber what intensity is right for you. This page explains the measurement problem, not the prescription. (mayoclinic.org)

Medications and heart-rate zones at a glance

Yes: medications can change the numbers your heart-rate zones are built on, because zones usually lean on resting heart rate, estimated max heart rate, or heart-rate reserve. If a drug lowers or raises your pulse, the watch may still show a clean “Zone 2” or “Zone 4,” but the physiology underneath has shifted. Beta-blockers are the clearest example: they block adrenergic signaling in the heart, slow heart rate, and blunt the heart-rate rise that normally happens as work gets harder. That makes heart-rate zones less transferable from a generic formula to your body on that medication. (ncbi.nlm.nih.gov)

The biggest downward shifts usually come from rate-lowering drugs. Beta-blockers are the main class to think about, and non-dihydropyridine calcium channel blockers — especially verapamil and diltiazem — can also slow the heart through effects on cardiac pacemaker and conduction tissue. That does not mean the medication is “bad” for exercise data. It means the heart-rate number is no longer the same signal it was before the drug. (ncbi.nlm.nih.gov)

For scale, one Cochrane review of nonselective beta-blockers in mild-to-moderate hypertension found about a 12 bpm heart-rate reduction at recommended starting doses; another official pindolol label notes that beta-blockers with intrinsic sympathomimetic activity can produce a smaller resting-heart-rate reduction, about 4–8 bpm, than drugs without that property. Treat those numbers as context, not math you apply to your zones. The same class can behave differently by drug, dose, condition, fitness, timing, and your own autonomic baseline. (pmc.ncbi.nlm.nih.gov)

GLP-1–based medications, including tirzepatide, point in the other direction but usually by much less. FDA review and labeling language for tirzepatide reports average heart-rate increases around 1–3 bpm in weight-management trials, and a PubMed-indexed meta-analysis in type 2 diabetes found a dose-response pattern, with the highest tirzepatide dose increasing heart rate by about 3 bpm versus placebo in network analysis. So GLP-1s can nudge the pulse upward, but that nudge is small compared with the typical downward shift seen with many beta-blockers. (accessdata.fda.gov)

That asymmetry is the practical point. A 2–3 bpm increase may show up in your trends, especially if you track carefully, but it is much easier to confuse with ordinary heart-rate movement from sleep, stress, temperature, posture, hydration, recent activity, or measurement timing. A 10–12 bpm medication effect is more likely to move the zone itself. This is why a wearable zone can stay visually “correct” while becoming less meaningful for comparing workouts before and after a medication change. (mayoclinic.org)

“220 minus age” does not solve this. It is widely used, but it is a population estimate, not a personal ceiling. Recent endurance-athlete data describe substantial individual variation and systematic underestimation in trained populations; other studies also show wide error around age-predicted max heart rate. If your max heart rate estimate is already rough, and a medication changes your chronotropic response on top of that, the zone becomes even less exact. (pubmed.ncbi.nlm.nih.gov)

HRV can shift too. Beta-blockers, anticholinergics, calcium channel blockers, antidepressants, and other autonomic-acting drugs can change HRV or are commonly treated as HRV confounders in studies. So if your HRV changes after starting or changing a medication, do not read it as a pure “recovery,” “stress,” or “illness” signal without considering the drug effect. (pmc.ncbi.nlm.nih.gov)

Use heart rate as one input, not the whole dashboard. Pair it with perceived exertion, breathing, the talk test, symptoms, and your own before-and-after baseline. If you can talk but not sing, you are generally in a moderate-effort range; if you cannot say more than a few words without pausing, the work is vigorous. And if you take a medication that affects heart rate, intensity limits should come from your prescriber or care team — not from adding or subtracting beats from a watch zone. (cdc.gov)

Heart-rate zones assume a heart that's free to respond

Heart-rate zones look precise, but they’re built on a fragile assumption. The system estimates your maximum heart rate, compares it with your resting rate, and cuts the space between them into “easy,” “moderate,” and “hard.” Under the hood, it assumes that as your muscles demand more oxygen, your pulse can climb in a predictable way — and that a higher number on your wrist means a higher level of physiological effort.

That works best when the signal chain is intact. You start moving harder; your sympathetic nervous system turns up the drive; the sinoatrial node fires faster; more blood moves through the body; your pulse rises. Clinicians call the size of that rise your chronotropic response, and they often describe it relative to your heart rate reserve — "Chronotropic index, defined as the percent of heart rate reserve used". In exercise-testing research, chronotropic index is commonly calculated from how much of your predicted heart-rate reserve you actually use during exercise, not from the wrist number in isolation. (pmc.ncbi.nlm.nih.gov)

When a medication interferes with that chain, the watch may still be measuring beats per minute correctly — but the meaning of those beats has changed. A drug that dampens adrenergic signaling or slows sinus-node firing can make the heart rise less, rise later, or sit lower at the same workload. In a randomized trial in healthy young adults, bisoprolol reduced resting and maximal heart rate and reduced the chronotropic response to exercise. (pubmed.ncbi.nlm.nih.gov) The sensor is not necessarily wrong. The translation layer is: “beats per minute” no longer maps cleanly onto “how hard your body is working.”

That is why this is a measurement-validity problem, not a motivation problem. If your heart-rate response is blunted, a workout can feel harder than the zone suggests. Your legs, breathing, temperature, and fatigue may be telling one story while the watch tells another. And a blunted response is not just a data inconvenience: "Low heart rate, i.e., chronotropic, response to exercise is known to contribute to reduced exercise capacity in other clinical populations". Exercise-test studies have linked impaired chronotropic response with lower exercise capacity in some groups, although the meaning depends on the condition, medication context, and how the response is defined. (pubmed.ncbi.nlm.nih.gov)

So the safest frame is not “adjust your zones” or “train harder to hit the number.” It is simpler: heart-rate zones assume a heart that is free to respond. If medication changes that response, the zone may no longer be a clean readout of effort.

The formula was shaky before any medication got involved

Before we blame medications, the baseline deserves scrutiny. Most consumer zone calculators still estimate maximum heart rate from age alone, and the research is blunt about it: "Conventional age-based HRmax prediction formulas, particularly the widely used "220-age" equation, remain common despite substantial individual variation" — and they "remain common despite substantial individual variation and documented underestimation in trained populations". In other words, the number your watch starts from may already be a rough guess, not a personal ceiling. (pubmed.ncbi.nlm.nih.gov)

Newer equations exist. The one embedded in the chronotropic-index calculation above uses `208 − (0.7 × age)` rather than `220 − age`; that equation comes from Tanaka, Monahan, and Seals’ age-predicted HRmax work. (pubmed.ncbi.nlm.nih.gov) It can be a better starting point in some settings, but swapping formulas does not remove the core problem: two people of the same age can still have meaningfully different true maximum heart rates, and validation studies continue to find individual-level spread around age-based predictions. (pmc.ncbi.nlm.nih.gov)

That matters for the rest of this article. Medication effects do not corrupt an otherwise precise system. They stack on top of an estimate that already carries meaningful personal error. Your zones may be dealing with two sources of uncertainty, not one.

Beta-blockers: the class that reshapes zones most

Beta-blockers are the clearest example of why a watch-based heart-rate zone can stop meaning what you think it means. During exercise, your body normally uses sympathetic signals — epinephrine and norepinephrine — to push the sinoatrial node to fire faster. Beta-1 receptors are a major part of that signal. When a beta-blocker occupies those receptors, the “speed up” message is muted: heart rate is lower at rest, and the climb during exertion is compressed. That is the point of the drug in many prescriptions, but it also means your zone 2, threshold, and “max HR” estimates may be built on a heart-rate response the medication is deliberately changing. (ncbi.nlm.nih.gov)

In hypertension trials, the size of that shift is large enough to matter. Cochrane reviews found that beta-1 selective beta-blockers reduced heart rate by about 11 bpm on average in people with mild-to-moderate primary hypertension, while nonselective beta-blockers reduced heart rate by about 12 bpm in a similar population. Those are group averages, not a personal correction factor. Your response can be smaller or larger depending on the drug, the dose your clinician chose, your baseline heart rate, your condition, and how your body handles the medication. (pubmed.ncbi.nlm.nih.gov)

The class is not uniform. Some beta-blockers have intrinsic sympathomimetic activity — a partial “on” signal at the receptor — so they tend to lower resting heart rate less than beta-blockers without that property. The official pindolol label puts it precisely: in humans, ISA "is manifested by a smaller reduction in the resting heart rate (4 to 8 beats/min) than is seen with drugs lacking ISA." In other words, the resting-heart-rate drop with an ISA drug is itself in the 4–8 bpm range — not a 4–8 bpm discount off some larger figure. The same label adds an important caveat: "the clinical significance of this observation has not been evaluated." A Cochrane review of partial-agonist beta-blockers likewise found a smaller average heart-rate reduction than with nonselective beta-blockers. (pindolol label — DailyMed/NLM) Acebutolol is also described in labeling as having mild ISA, with a slightly smaller resting-heart-rate decrease than comparable beta-blocking doses of propranolol, metoprolol, or atenolol. (dailymed.nlm.nih.gov)

Other agents change the picture in different ways. Atenolol, metoprolol, and bisoprolol are classic beta-1 selective rate-lowerers, so their effect is especially relevant when you are using heart rate to judge exercise intensity. Labetalol combines nonselective beta-blockade with alpha-1 blockade; its labeling describes a small decrease in resting heart rate and blunting of exercise-related tachycardia. Nebivolol is different again: it is beta-1 selective and also produces nitric-oxide-mediated vasodilation. That does not mean it leaves heart rate alone — reviews report that nebivolol decreases resting and exercise heart rate — but its vasodilating profile can preserve stroke volume and cardiac output in ways that make it hemodynamically different from older “plain” rate-lowering beta-blockers. (ncbi.nlm.nih.gov)

Genetics add another layer. Metoprolol is mainly metabolized through CYP2D6, and CYP2D6 activity varies widely between people. CPIC guidance reports that, compared with normal metabolizers, CYP2D6 poor metabolizers taking the same metoprolol dose can have a more than two-fold longer elimination half-life and nearly five-fold higher drug exposure; the same guidance links that higher exposure to greater heart-rate reduction, roughly 3–8 bpm more in the evidence it reviewed. So two people can take the same named drug and still see meaningfully different heart-rate data on the watch. (pmc.ncbi.nlm.nih.gov)

That is why “add 20 bpm if you’re on a beta-blocker” is not a real answer. It treats a prescription as if it were one predictable mathematical filter. It is not. The agent, formulation, dose, timing, diagnosis, fitness level, and metabolism all shape the signal. If you use heart-rate zones while taking a beta-blocker, the safest interpretation is not “my fitness suddenly changed” or “my watch is wrong.” It is: your watch is measuring a real heart rate, but that heart rate may no longer map cleanly onto standard zone formulas.

What this does not mean: it does not mean the medication is a problem to work around. Rate-lowering is often the therapeutic point. Beta-blockers are used across conditions where slowing the heart, reducing myocardial oxygen demand, controlling rhythm, or improving outcomes is part of the treatment plan. The measurement problem is a side effect of effective treatment, not a reason to change, skip, or “outsmart” the prescription. Any intensity guidance while taking a beta-blocker should come from the clinician who knows why you are taking it. (ncbi.nlm.nih.gov)

Calcium channel blockers: the quieter rate-lowerers

Calcium channel blockers are not one heart-rate story. Verapamil and diltiazem sit in the non-dihydropyridine group, and they can make wearable heart-rate zones harder to interpret because they act directly on the heart’s pacing and conduction tissue. Instead of blocking adrenaline signals the way beta-blockers do, they block L-type calcium channels in the sinoatrial and atrioventricular nodes. In the body, that can mean slower nodal automaticity, slower AV-node conduction, and a heart rate that may not climb the way your watch expects during effort. (pmc.ncbi.nlm.nih.gov)

That is why they belong in this conversation. Many people recognize beta-blockers as “heart rate drugs,” but do not think of verapamil or diltiazem the same way. Yet clinically, these drugs are used precisely because they can slow ventricular rate and affect AV-node conduction, including during activity in some rhythm conditions. For a wearable, the practical issue is not whether the medication is “good” or “bad.” It is that the number on your wrist may no longer map cleanly onto the training-zone promise behind it. (pmc.ncbi.nlm.nih.gov)

Their dihydropyridine cousins — amlodipine, nifedipine, felodipine — behave differently. They are more vascular-selective: they lower blood pressure mainly through the blood vessels rather than by slowing the heart’s electrical nodes. So they do not usually have the same rate-lowering effect as verapamil or diltiazem, and some dihydropyridines can cause a reflex rise in heart rate, especially when vasodilation happens quickly. (pmc.ncbi.nlm.nih.gov)

For this class, do not use a fixed “add-back” number. The clean takeaway is direction and mechanism: verapamil and diltiazem are commonly reported to slow heart rate; dihydropyridines generally do not behave like rate-slowing drugs and may sometimes raise heart rate reflexively. If you take one of these medications, your wearable heart-rate zones may be less valid as a readout of effort, recovery, or fitness change. The medication may be changing the signal before your watch ever interprets it.

Medications that nudge heart rate up — including GLP-1s

The effect runs both ways. Some medications can pull your heart rate down; others can push it up. But the size of the push matters, and this is where the popular story often loses proportion.

GLP-1 receptor agonists. Tirzepatide has been studied in people with obesity-related heart failure with preserved ejection fraction in the SUMMIT trial, and FDA-reviewed tirzepatide trial data describe a small average heart-rate increase — about 1 to 3 beats per minute compared with no increase on placebo. In a SURMOUNT-1 ambulatory blood pressure substudy, the placebo-adjusted heart-rate increase at 36 weeks was 2.1, 2.3, and 5.4 bpm across treatment groups; the longer SURMOUNT-1 trial reported smaller pulse changes by 72 weeks, around 0.6 to 2.6 bpm from baseline versus 0.1 bpm with placebo. (pubmed.ncbi.nlm.nih.gov)

Put that next to a rate-lowering medication and the asymmetry is the story. Beta-blocker reviews in hypertension trials report heart-rate reductions around 11 to 12 bpm versus placebo — large enough to shift what a “zone 2” or “threshold” number means on a watch. A GLP-1-related rise of a few beats is a much smaller signal, and it can sit in the same noisy range as caffeine, dehydration, heat, illness, stress, or a rough night of sleep. (pmc.ncbi.nlm.nih.gov)

So if you’re worried that a GLP-1 has completely invalidated your training zones, the evidence doesn’t point there. The bigger blind spot is the opposite pattern: being on a medication that lowers heart rate and still treating your watch zones as if your heart-rate response were unchanged.

Decongestants. Pseudoephedrine is a useful comparison because it’s over the counter and easy to forget when you’re sick. A meta-analysis of oral pseudoephedrine found a mean heart-rate increase of about 2.83 bpm; a later exercise-focused meta-analysis also found a small positive effect on heart rate, with an effect size of 0.43. That is the same general order of magnitude as the smaller GLP-1 signal — from a cold medicine. (pubmed.ncbi.nlm.nih.gov)

Other medications can nudge the number upward too: thyroid hormone replacement when the dose is more than your body needs, some asthma inhalers such as beta-agonists, stimulants used for ADHD, and anticholinergic drugs. The mechanism is different in each case — thyroid signaling, airway beta-receptor stimulation, sympathetic nervous system activation, or reduced parasympathetic braking — but the practical consequence is the same: the number on the screen moves, while the zone map on the app does not automatically know why. (medlineplus.gov)

Recovery scores and HRV shift too

Heart rate isn't the only number that drifts on medication. Recovery scores, readiness verdicts, "stress," and most HRV-derived insights are built from the spacing between heartbeats. If a drug changes those intervals, it also changes whatever your app turns them into. The research literature describes HRV as a measure sensitive to a wide range of physiological, behavioural, environmental, and methodological factors — and medication sits squarely inside that list as something interpretation has to account for. (pubmed.ncbi.nlm.nih.gov)

The research states it directly: "Medications, particularly beta-blockers and anticholinergics, dramatically alter HRV independent of disease status". The crucial phrase is independent of disease status. If your HRV shifts after starting, stopping, or changing a medication, that does not automatically mean you recovered better, overtrained, or that your health deteriorated. It may mean something simpler: the pharmacology changed how your heart's autonomic regulation behaves, and the algorithm only sees the new shape of the signal. Work on anticholinergic drugs and antihypertensive therapy indicates that different drug classes can move HRV in different ways, so the same numeric shift can't be read outside the context of what was prescribed. (pubmed.ncbi.nlm.nih.gov)

That makes an automated verdict like "ready to perform" or "poor recovery" less dependable when the app has no idea your therapy changed. It can still sound confident — but an algorithm's confidence isn't clinical meaning. This matters most for people who start treating a recovery score as an instruction: train, rest, push harder, or abandon the plan. Wearable services often deliver personalised prompts, yet many of these scores rest on proprietary algorithms, and user-facing research suggests readiness and recovery scores work best alongside how you actually feel — not as a standalone diagnosis or directive. (pubmed.ncbi.nlm.nih.gov)

None of this is a reason to stop measuring. The data can stay useful — it just has to be read more honestly. After a settled change in therapy, compare yourself with yourself in the new state: sleep, symptoms, training load, morning heart rate, HRV trend, subjective recovery. An old baseline collected before the medication may no longer be a fair reference point. Population norms don't help much either, because HRV depends heavily on measurement context — age, sex, fitness, time of day, body position, breathing, the device, and the calculation method. (pubmed.ncbi.nlm.nih.gov)

The practical takeaway is straightforward: if a medication changes the signal, your app may get the story about your body wrong. Keep tracking trends — but don't adjust doses, skip medication, or rearrange treatment to chase a better recovery score. And if new symptoms arrive alongside the numbers after a medication change — marked weakness, fainting, unusual breathlessness, chest pain, a racing heart, or severe dizziness — that isn't a metrics-optimisation question. That's a reason to talk to your doctor.

What to lean on instead

None of this means heart rate is useless. It means a formula-derived zone should move down a notch: not a verdict, not a command, but one signal among several. When medication changes how fast your heart can respond, the safer question is not “what number should I force my pulse to hit?” It is “what else can help me interpret this effort?”

• Perceived exertion. Borg-style RPE asks you to rate how hard the work feels: breathing, muscle effort, fatigue, the sense of strain in your body. That matters because some medications can flatten or shift the heart-rate response, while perceived effort can still give you a usable read on intensity. It is widely used in exercise science and is specifically discussed as an alternative way to judge effort when beta blockers make target heart rate less reliable. (cdc.gov)

• The talk test. Your voice is a low-tech sensor. If you can talk but not sing, the effort is usually in a moderate range; if talking becomes difficult, the work is getting harder. The talk test is practical because it does not need a watch, a max-heart-rate formula, or a clean medication-free baseline, and research describes it as a valid, inexpensive tool for monitoring exercise intensity in health and cardiac settings. (pmc.ncbi.nlm.nih.gov)

• Your own measured range, not an estimated one. The `220 − age` shortcut is an average, and averages can miss the person in front of them. Studies comparing age-predicted and measured maximum heart rate show wide individual error, and recent endurance-athlete data found that age formulas can underestimate observed maximum heart rate with broad limits of agreement. A reference range built from your actual heart-rate patterns while you are on your current medication is therefore more meaningful than treating `220 − age` as your body’s truth. (pubmed.ncbi.nlm.nih.gov)

• Trends over single sessions. One workout can be distorted by sleep, heat, stress, caffeine, illness, dehydration, sensor fit, and timing of medication. A pattern across weeks is harder to fake. If the same walk, ride, or run starts producing a different heart-rate-and-effort pattern again and again, that trend is more informative than one strange spike or one unusually low day.

• A conversation with your prescriber. If you take a medication affecting heart rate and want to train, appropriate intensity is a clinical question — ask the person who prescribed it. Beta blockers, for example, can keep heart rate from rising as expected during exercise, and sources from the American Heart Association and Mayo Clinic emphasize that people may need clinician help rather than self-adjusted target zones. Some people are advised to use perceived exertion because heart rate is unreliable for them. (heart.org)

What we are not doing on this page: giving target zones, correction factors, or intensity prescriptions for anyone on medication. That is a clinical decision, and it depends on the drug, the dose, the condition being treated, and the person.

The Welltory angle: your baseline, not a formula

This is where wearable data earns its place — if the framing stays honest.

A medication that lowers or reshapes your heart-rate response can break the usual zone logic. Beta-blockers, for example, can lower resting and exercise heart rate and blunt the chronotropic response — the normal rise in heart rate as your body asks for more oxygen during effort. That means a “low” number on your watch may reflect pharmacology, not suddenly improved fitness, and a zone based on a population formula may be describing a heart that is not behaving like yours right now. (pubmed.ncbi.nlm.nih.gov)

Welltory’s useful angle is not to pretend it can correct that with a magic adjustment. It is to keep the comparison personal: what your resting heart rate, exercise response, and HRV usually look like for you, and whether they are drifting away from that pattern. Research on wearable monitoring increasingly uses this kind of within-person baseline approach, because changes from your own recent normal can be more meaningful than a single number judged against a generic chart. (pubmed.ncbi.nlm.nih.gov)

There are two caveats you should keep in view. First, Welltory cannot see your prescriptions. The app does not know that a beta-blocker, calcium-channel blocker, stimulant, thyroid medication, or any other drug is part of the picture. So neither you nor an app should read a lower heart rate as automatic proof that your cardiovascular fitness improved. Second, if you started a medication and your numbers changed, your new on-medication baseline is the reference that matters now. Comparing every reading with your pre-medication self will mostly measure the medication’s effect on your physiology, not your current recovery or resilience.

HRV needs the same humility. Some medications can alter HRV or make it harder to interpret, so the number is not a clean window into “stress” or “readiness” in isolation. It becomes more useful when you look at it together with context: sleep, symptoms, illness, training load, blood pressure if you track it, and how the effort actually feels in your body. (pubmed.ncbi.nlm.nih.gov)

Used this way, your wearable data becomes something concrete to bring to a clinician: here is my typical resting heart rate and HRV since starting this medication; here is what happens when I walk, climb stairs, or exercise; here is what feels sustainable; here is what feels unusual. That is a better starting point than a zone chart that assumed nobody had adjusted your heart’s signal.

Related reading: heart rate variability, resting heart rate, blood pressure, POTS.

How we made it

Made with AI tools, then edited, fact-checked, and medically reviewed by the Welltory team.

Discounts for blog readers: up to 36% off

See what affects your energy, stress, sleep, and daily state with Welltory

Explore your data